MuvonJan 92 min readMUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference
MuvonJul 30, 20242 min readMuvon Therapeutics announces the appointment of Marcus Droege as Chief Commercial Officer
MuvonDec 7, 20231 min readLadies Drive Interview with Deana Mohr & Jenny Prange on Female Innovator of the Year Award
MuvonJun 12, 20231 min readMUVON Therapeutics AG among the TOP 3 Swiss biotech leaders according to public voting
MuvonJun 2, 20231 min readMUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy
MuvonApr 24, 20231 min readFirst in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy
MuvonDec 22, 20221 min readThe leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023
MuvonNov 16, 20223 min readMUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board
MuvonOct 27, 20223 min readMuvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study
MuvonSep 19, 20221 min readCEO Deana Mohr honored to present MUVON to Prof. Shinya Yamanaka, godfather of iPSCs
